Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patie...

Descripción completa

Detalles Bibliográficos
Autores principales: S. Ahmad, Saif, Qian, Wendi, Ellis, Sarah, Mason, Elaine, Khattak, Muhammad A., Gupta, Avinash, Shaw, Heather, Quinton, Amy, Kovarikova, Jarmila, Thillai, Kiruthikah, Rao, Ankit, Board, Ruth, Nobes, Jenny, Dalgleish, Angus, Grumett, Simon, Maraveyas, Anthony, Danson, Sarah, Talbot, Toby, Harries, Mark, Marples, Maria, Plummer, Ruth, Kumar, Satish, Nathan, Paul, Middleton, Mark R., Larkin, James, Lorigan, Paul, Wheater, Matthew, Ottensmeier, Christian H., Corrie, Pippa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
ORIGINAL ARTICLES: Clinical research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560270/
https://www.ncbi.nlm.nih.gov/pubmed/26225580
http://dx.doi.org/10.1097/CMR.0000000000000185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560270/
https://www.ncbi.nlm.nih.gov/pubmed/26225580
http://dx.doi.org/10.1097/CMR.0000000000000185

Ejemplares similares